Distractibility in ADHD associated with reduced ability to modulate alpha band oscillations in attentional tasks

Distractibility in ADHD associated with reduced ability to modulate alpha band oscillations in attentional tasks - SHARK 2.0

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43451

Enrollment

Registered

2016-06-30

Start date

2016-10-06

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD attention deficit and hyperactivity disorder

Interventions

None listed

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: For both groups inclusion criteria will be: (1) Age between 8 and 12 years. (2) Enrolled in primary (not secondary) school. (3) Estimated IQ above 80. For the ADHD-group an additional inclusion criterion will be: (1) a clinical diagnosis of ADHD according to the criteria of the DSM-V (see *Study procedures* for detailed description). (2) Scored in the clinical range on the ADHD DSM-IV rating scale, completed by parents. (3) Pharmacological treatment with Methylphenidate (either long- or short-acting formulations), which started at least 3 months before the inclusion in the study.

Exclusion criteria

Exclusion criteria: For both groups exclusion criteria will be: (1) (Co-morbid) psychiatric disorder (major depression, bipolar disorder, psychotic disorder, chronically motor tic disorder or Gilles de la Tourette, Conduct disorder, autism spectrum disorder, eating disorder, anxiety disorder). (2) Neurological disorders (e.g. epilepsy) currently or in the past. (3) Cardiovascular disease currently or in the past. (4) Serious motor or perceptual handicap. (5) Standard MRI Exclusion criteria according to DCCN regulations (see attached pdf in cmo application section: K6: *MR algemene informatie*).

Design outcomes

Primary

Measure	Time frame
Alpha Modulation Index (AMI) and Alpha Lateralization Index (ALI) will be computed and compared between ADHD and control groups and within ADHD between on- and off-medication conditions; Furthermore the volume of the Superior Longitudinal fascicles will be estimated by means of DTI analysis and the volume of the striatum by means of voxel based morphometry analysis of MRI data. Primary analysis will then focus on: - Difference in ALI and AMI between patients and controls and within patients, between conditions MPH and placebo. - Difference in SLF volume between patients and control. - Correlation between ALI and SLF lateralization. - Difference in striatal brain volume between patients and controls. - Correlation between striatal volume and Alpha Modulation Index.	—

Measure

Time frame

Alpha Modulation Index (AMI) and Alpha Lateralization Index (ALI) will be computed and compared between ADHD and control groups and within ADHD between on- and off-medication conditions; Furthermore the volume of the Superior Longitudinal fascicles will be estimated by means of DTI analysis and the volume of the striatum by means of voxel based morphometry analysis of MRI data. Primary analysis will then focus on: - Difference in ALI and AMI between patients and controls and within patients, between conditions MPH and placebo. - Difference in SLF volume between patients and control. - Correlation between ALI and SLF lateralization. - Difference in striatal brain volume between patients and controls. - Correlation between striatal volume and Alpha Modulation Index.

—

Countries

Netherlands

Outcome results